NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit<
13 Jun 2024

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit

The US-based pivotal trial follows strong 12-month data from the first-in-human trial in Europe

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline<
29 May 2024

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP
Memo Therapeutics increases Series C financing to CHF 45 million<
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors.
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights<
27 Mar 2024

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update<
21 Mar 2024

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mineralys Therapeutics 4Q and Full Year 2023 Financial Results
Lava provides business updates and reports fourth quarter and year-end financial results<
20 Mar 2024

Lava provides business updates and reports fourth quarter and year-end financial results

Strong balance sheet with cash of $95.6 million supports runway into 2026
Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies<
20 Mar 2024

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorder
Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer<
19 Mar 2024

Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer

Total transaction value of approximately $2.4 billion including the CVR
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)<
21 Feb 2024

NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)

Study strengthens NST’s position as a multi-asset, clinical stage company
Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders<
09 Feb 2024

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

This financing follows promising early clinical data from NRTX-1001 epilepsy program.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка